-
鼻咽癌是一种起源于鼻咽上皮内黏膜的头颈部肿瘤,在中国和东南亚国家中高发[1]。由于早期症状不典型,70%的患者在初诊时已是局部晚期[2]。近年来,调强适形放射治疗(intensity-modulated radiation therapy,IMRT)的出现明显提高了鼻咽癌患者的生存率[3]。令人惋惜的是,鼻咽癌一旦发生转移,患者5年生存率仍低至15%[3]。目前TNM分期是预测鼻咽癌预后、指导不同风险人群治疗策略制定最主要的工具;然而,处于同一分期的患者治疗效果往往不同[4]。这可能与TNM分期只考虑了肿瘤浸润的解剖结构,没有考虑肿瘤细胞或患者机体的功能状态有关[5]。因此,确定其他独立预后因素,从而推动鼻咽癌患者的个性化诊治,提高临床干预的准确性和有效性是非常必要的。
最新的中国临床肿瘤学会(CSCO)及美国国立综合癌症网络 (NCCN)指南均建议在治疗高危鼻咽癌患者前使用18F-FDG PET/CT显像评估患者病情[6-7]。18F-FDG PET/CT作为一种非侵入性的分子影像显像技术,可同时提供肿瘤的解剖和功能信息,已被广泛应用于包括鼻咽癌在内的各种肿瘤的精准分期、预后预测等[8]。此外,越来越多的研究结果表明炎症在肿瘤的发生、侵袭和转移中起着关键作用[9]。总之,18F-FDG PET/CT参数和炎症标志物与鼻咽癌患者的生存显著相关。本文综述了对鼻咽癌预后具有重要预测价值的相关指标。
18F-FDG PET/CT参数和炎症标志物在鼻咽癌预后预测中的应用进展
Application progress on 18F-FDG PET/CT parameters and inflammatory markers in prognostic prediction of nasopharyngeal carcinoma
-
摘要: 鼻咽癌是一种在中国及东南亚国家高发的头颈部恶性肿瘤,具有易复发、易转移的特点。临床上,18F-氟脱氧葡萄糖(FDG)PET/CT显像及生化指标监测已成为管理鼻咽癌患者必不可少的一环。18F-FDG PET/CT参数和炎症标志物的联合应用可能在提高鼻咽癌诊断准确率及开展个体化治疗方面具有巨大潜力,并对鼻咽癌患者临床预后的改善起到重要作用。笔者系统地综述了18F-FDG PET/CT参数和炎症标志物在鼻咽癌患者预后预测中的应用进展。
-
关键词:
- 鼻咽癌 /
- 炎症 /
- 氟脱氧葡萄糖F18 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 预后
Abstract: Nasopharyngeal carcinoma is a malignant tumor prevalent in China and Southeast Asian countries, characterized by a high recurrence and metastasis rate. Clinically, 18F-fluorodeoxyglucose (FDG) PET/CT imaging and monitoring of biochemical indicators have become indispensable components of the management of patients with nasopharyngeal carcinoma. The combined use of 18F-FDG PET/CT and inflammatory markers may have significant potential in improving the accuracy of nasopharyngeal carcinoma diagnosis and personalized treatment. This combination also plays a crucial role in enhancing the clinical prognosis of nasopharyngeal carcinoma patients. The authors systematically reviewed the application progress of 18F-FDG PET/CT parameters and inflammatory markers in predicting the prognosis of nasopharyngeal carcinoma patients. -
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209−249. DOI: 10.3322/caac.21660. [2] Zhang YT, Rumgay H, Li MM, et al. Nasopharyngeal cancer incidence and mortality in 185 countries in 2020 and the projected burden in 2040: population-based global epidemiological profiling[J/OL]. JMIR Public Health Surveill, 2023, 9: e49968[2023-04-10]. https://publichealth.jmir.org/2023/1/e49968. DOI: 10.2196/49968. [3] Liang YJ, Liu LT, Li Y, et al. Association of treatment advances with survival rates in pediatric patients with nasopharyngeal carcinoma in China, 1989-2020[J/OL]. JAMA Netw Open, 2022, 5(3): e220173[2023-04-10]. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789571. DOI: 10.1001/jamanetworkopen.2022.0173. [4] Du XJ, Wang GY, Zhu XD, et al. Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma[J]. Cancer Cell, 2024, 42: 1−10. DOI: 10.1016/j.ccell.2023.12.020. [5] Zhuo EH, Zhang WJ, Li HJ, et al. Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups[J]. Eur Radiol, 2019, 29(10): 5590−5599. DOI: 10.1007/s00330-019-06075-1. [6] Tang LL, Chen YP, Chen CB, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma[J/OL]. Cancer Commun (Lond), 2021, 41(11): 1195−1227[2023-04-10]. https://onlinelibrary.wiley.com/doi/10.1002/cac2.12218. DOI: 10.1002/cac2.12218. [7] Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2. 2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(7): 873−898. DOI: 10.6004/jnccn.2020.0031. [8] Yang SS, Wu YS, Chen WC, et al. Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma[J]. Eur J Nucl Med Mol Imaging, 2022, 49(3): 980−991. DOI: 10.1007/s00259-021-05540-8. [9] Dash SR, Kundu A, Kundu CN. The role of viruses in cancer progression versus cancer treatment: a dual paradigm[J]. Life Sci, 2024, 341: 122506. DOI: 10.1016/j.lfs.2024.122506. [10] Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging[J]. J Nucl Med, 2007, 48(6): 932−945. DOI: 10.2967/jnumed.106.035774. [11] Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe[J]. Clin Cancer Res, 2009, 15(2): 425−430. DOI: 10.1158/1078-0432.Ccr-08-0149. [12] Xie P, Yue JB, Fu Z, et al. Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma[J]. Ann Oncol, 2010, 21(5): 1078−1082. DOI: 10.1093/annonc/mdp430. [13] Hung TM, Wang HM, Kang CJ, et al. Pretreatment 18F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma[J]. Oral Oncol, 2013, 49(2): 169−174. DOI: 10.1016/j.oraloncology.2012.08.011. [14] Gihbid A, Salhi GC, El Alami I, et al. Pretreatment [18F]FDG PET/CT and MRI in the prognosis of nasopharyngeal carcinoma[J]. Ann Nucl Med, 2022, 36(10): 876−886. DOI: 10.1007/s12149-022-01770-4. [15] Hung TM, Fan KH, Kang CJ, et al. Lymph node-to-primary tumor standardized uptake value ratio on PET predicts distant metastasis in nasopharyngeal carcinoma[J]. Oral Oncol, 2020, 110: 104756. DOI: 10.1016/j.oraloncology.2020.104756. [16] Shen EYL, Hung TM, Tsan DL, et al. Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma[J]. Radiother Oncol, 2022, 177: 1−8. DOI: 10.1016/j.radonc.2022.05.004. [17] Lin J, Xie GZ, Liao GX, et al. Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis[J/OL]. Oncotarget, 2017, 8(20): 33884−33896[2023-04-10]. https://www.oncotarget.com/article/13934/text. DOI: 10.18632/oncotarget.13934. [18] Chan SC, Yeh CH, Chang JTC, et al. Combing MRI perfusion and 18F-FDG PET/CT metabolic biomarkers helps predict survival in advanced nasopharyngeal carcinoma: a prospective multimodal imaging study[J/OL]. Cancers (Basel), 2021, 13(7): 1550[2023-04-10]. https://www.mdpi.com/2072-6694/13/7/1550. DOI: 10.3390/cancers13071550. [19] Yang ZY, Shi Q, Zhang YP, et al. Pretreatment 18F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma—a retrospective study[J/OL]. Radiat Oncol, 2015, 10: 4[2023-04-10]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-014-0268-5. DOI: 10.1186/s13014-014-0268-5. [20] Xiong SM, Dong LL, Cheng L. Neutrophils in cancer carcinogenesis and metastasis[J/OL]. J Hematol Oncol, 2021, 14(1): 173[2023-04-10]. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01187-y. DOI: 10.1186/s13045-021-01187-y. [21] He JR, Shen GP, Ren ZF, et al. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma[J]. Head Neck, 2012, 34(12): 1769−1776. DOI: 10.1002/hed.22008. [22] Lu J, Chen XM, Huang HR, et al. Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma[J]. Head Neck, 2018, 40(6): 1245−1253. DOI: 10.1002/hed.25104. [23] Chen LS, Li MY, Xu T, et al. Prognostic value of neutrophils for patients with nasopharyngeal carcinoma[J/OL]. Laryngoscope Investig Otolaryngol, 2021, 6(2): 219−225[2023-04-10]. https://onlinelibrary.wiley.com/doi/10.1002/lio2.548. DOI: 10.1002/lio2.548. [24] Szkandera J, Gerger A, Liegl-Atzwanger B, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas[J]. Int J Cancer, 2014, 135(2): 362−370. DOI: 10.1002/ijc.28677. [25] Li J, Jiang R, Liu WS, et al. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma[J/OL]. PLoS One, 2013, 8(12): e83069[2023-04-10]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083069. DOI: 10.1371/journal.pone.0083069. [26] Liu LT, Liang YJ, Guo SS, et al. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA[J]. Head Neck, 2022, 44(1): 34−45. DOI: 10.1002/hed.26897. [27] Ostroumov D, Fekete-Drimusz N, Saborowski M, et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth[J]. Cell Mol Life Sci, 2018, 75(4): 689−713. DOI: 10.1007/s00018-017-2686-7. [28] Wang YQ, Chen YP, Zhang Y, et al. Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: a large-scale cohort study[J]. Int J Cancer, 2018, 142(12): 2558−2566. DOI: 10.1002/ijc.31279. [29] Cai ZC, Jiang JL, Huang LJ, et al. The prognostic impact of combined tumor-infiltrating lymphocytes and pretreatment blood lymphocyte percentage in locally advanced nasopharyngeal carcinoma[J/OL]. Front Oncol, 2021, 11: 788497[2023-04-10]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.788497/full. DOI: 10.3389/fonc.2021.788497. [30] Marone G, Varricchi G, Loffredo S, et al. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis[J]. Eur J Pharmacol, 2016, 778: 146−151. DOI: 10.1016/j.ejphar.2015.03.088. [31] Grisaru-Tal S, Dulberg S, Beck L, et al. Metastasis-entrained eosinophils enhance lymphocyte-mediated antitumor immunity[J]. Cancer Res, 2021, 81(21): 5555−5571. DOI: 10.1158/0008-5472.CAN-21-0839. [32] Zeng XJ, Liu GH, Pan YB, et al. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma[J]. J Cell Mol Med, 2020, 24(15): 8326−8349. DOI: 10.1111/jcmm.15097. [33] Schlesinger M. Role of platelets and platelet receptors in cancer metastasis[J/OL]. J Hematol Oncol, 2018, 11(1): 125[2023-04-10]. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0669-2. DOI: 10.1186/s13045-018-0669-2. [34] Li F, Xu T, Chen PL, et al. Platelet-derived extracellular vesicles inhibit ferroptosis and promote distant metastasis of nasopharyngeal carcinoma by upregulating ITGB3[J/OL]. Int J Biol Sci, 2022, 18(15): 5858−5872[2023-04-10]. https://www.ijbs.com/v18p5858.htm. DOI: 10.7150/ijbs.76162. [35] Chen YP, Chen C, Mai ZY, et al. Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients[J]. Oncol Lett, 2015, 9(3): 1458−1466. DOI: 10.3892/ol.2015.2872. [36] Mishra D, Banerjee D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment[J/OL]. Cancers (Basel), 2019, 11(6): 750[2023-04-10]. https://www.mdpi.com/2072-6694/11/6/750. DOI: 10.3390/cancers11060750. [37] Dhup S, Dadhich RK, Porporato PE, et al. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis[J]. Curr Pharm Des, 2012, 18(10): 1319−1330. DOI: 10.2174/138161212799504902. [38] Huang L, Sim AYL, Wu YZ, et al. Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma[J]. Ther Adv Med Oncol, 2020, 12: 1758835920970050. DOI: 10.1177/1758835920970050. [39] Liaw CC, Wang CH, Huang JS, et al. Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma[J]. Acta Oncol, 1997, 36(2): 159−164. DOI: 10.3109/02841869709109224. [40] Wan XB, Wei L, Li H, et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma[J]. Eur J Cancer, 2013, 49(10): 2356−2364. DOI: 10.1016/j.ejca.2013.03.008. [41] Bellelli A, Tame JRH. Hemoglobin allostery and pharmacology[J]. Mol Aspects Med, 2022, 84: 101037. DOI: 10.1016/j.mam.2021.101037. [42] Yuan M, Liang S, Zhou Y, et al. A robust oxygen-carrying hemoglobin-based natural sonosensitizer for sonodynamic cancer therapy[J]. Nano Lett, 2021, 21(14): 6042−6050. DOI: 10.1021/acs.nanolett.1c01220. [43] Prosnitz RG, Yao B, Farrell CL, et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer[J]. Int J Radiat Oncol Biol Phys, 2005, 61(4): 1087−1095. DOI: 10.1016/j.ijrobp.2004.07.710. [44] Guo SS, Tang LQ, Chen QY, et al. Is hemoglobin level in patients with nasopharyngeal carcinoma still a significant prognostic factor in the era of intensity-modulated radiotherapy technology?[J/OL]. PLoS One, 2015, 10(8): e0136033[2023-04-10]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136033. DOI: 10.1371/journal.pone.0136033. [45] Zhang LL, Zhou GQ, Li YY, et al. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: a large-scale retrospective study[J/OL]. Cancer Med, 2017, 6(12): 2822−2831[2023-04-10]. https://onlinelibrary.wiley.com/doi/10.1002/cam4.1233. DOI: 10.1002/cam4.1233. [46] Ruan GT, Xie HL, Yuan KT, et al. Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia[J]. J Cachexia Sarcopenia Muscle, 2023, 14(6): 2813−2823. DOI: 10.1002/jcsm.13358. [47] Tang LQ, Hu DP, Chen QY, et al. Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era[J/OL]. PLoS One, 2015, 10(4): e0122965[2023-04-10]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122965. DOI: 10.1371/journal.pone.0122965. [48] Chen RW, Zhou Y, Yuan YJ, et al. Effect of CRP and kinetics of CRP in prognosis of nasopharyngeal carcinoma[J/OL]. Front Oncol, 2019, 9: 89[2023-04-10]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00089/full. DOI: 10.3389/fonc.2019.00089. [49] Yang HF, Wang K, Liang Z, et al. Prognostic role of pre-treatment serum albumin in patients with nasopharyngeal carcinoma: a meta-analysis and systematic review[J]. Clin Otolaryngol, 2020, 45(2): 167−176. DOI: 10.1111/coa.13454. [50] Gao N, Yang RN, Meng Z, et al. The prognostic value of C-reactive protein/albumin ratio in nasopharyngeal carcinoma: a meta-analysis[J]. Biosci Rep, 2018, 38(6): BSR20180686. DOI: 10.1042/BSR20180686. [51] Yang SS, Zhao K, Ding X, et al. Prognostic significance of hematological markers for patients with nasopharyngeal carcinoma: a meta-analysis[J/OL]. J Cancer, 2019, 10(11): 2568−2577[2023-04-10]. https://www.jcancer.org/v10p2568.htm. DOI: 10.7150/jca.26770. [52] An X, Ding PR, Wang FH, et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma[J]. Tumour Biol, 2011, 32(2): 317−324. DOI: 10.1007/s13277-010-0124-7. [53] Chen C, Sun P, Dai QS, et al. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma[J/OL]. PLoS One, 2014, 9(11): e112581[2023-04-10]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0112581. DOI: 10.1371/journal.pone.0112581. [54] Jiang R, Zou X, Hu W, et al. The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients[J]. Tumour Biol, 2015, 36(10): 7775−7787. DOI: 10.1007/s13277-015-3505-0. [55] Li XH, Chang H, Xu BQ, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study[J/OL]. Cancer Med, 2017, 6(1): 310−319[2023-04-10]. https://onlinelibrary.wiley.com/doi/10.1002/cam4.947. DOI: 10.1002/cam4.947. [56] Ma MZ, Weng MZ, Chen F, et al. Systemic inflammation score is a prognostic marker after curative resection in gastric cancer[J]. ANZ J Surg, 2019, 89(4): 377−382. DOI: 10.1111/ans.15103. [57] Jiang WJ, Chen Y, Huang J, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis[J/OL]. Oncotarget, 2017, 8(39): 66075−66086[2023-04-10]. https://www.oncotarget.com/article/19796/text. DOI: 10.18632/oncotarget.19796. [58] Chen Y, Jiang WJ, Xi D, et al. Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas[J]. J Investig Med, 2019, 67(3): 691−698. DOI: 10.1136/jim-2018-000801. [59] Zeng XJ, Liu GH, Pan YB, et al. Prognostic value of clinical biochemistry-based indexes in nasopharyngeal carcinoma[J/OL]. Front Oncol, 2020, 10: 146[2023-04-10]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00146/full. DOI: 10.3389/fonc.2020.00146. [60] Zhong LT, Li CM, Ren YY, et al. Prognostic value of 18F-fluorodeoxyglucose PET parameters and inflammation in patients with nasopharyngeal carcinoma[J]. Oncol Lett, 2017, 14(4): 5004−5012. DOI: 10.3892/ol.2017.6816. [61] Xiao BB, Lin DF, Sun XS, et al. Nomogram for the prediction of primary distant metastasis of nasopharyngeal carcinoma to guide individualized application of FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2021, 48(8): 2586−2598. DOI: 10.1007/s00259-020-05128-8. [62] Xian WJ, Feng YL, Wang Y, et al. Usefulness of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography combined with the platelet-lymphocyte ratio in predicting the prognosis of nasopharyngeal carcinoma[J]. Br J Radiol, 2022, 95(1129): 20210279. DOI: 10.1259/bjr.20210279. [63] Chiang CL, Guo QJ, Ng WT, et al. Prognostic factors for overall survival in nasopharyngeal cancer and implication for TNM staging by UICC: a systematic review of the literature[J/OL]. Front Oncol, 2021, 11: 703995[2023-04-10]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.703995/full. DOI: 10.3389/fonc.2021.703995.
计量
- 文章访问数: 6870
- HTML全文浏览量: 6275
- PDF下载量: 8